Jeff Jones
Stock Analyst at Oppenheimer
(4.54)
# 1,031
Out of 4,994 analysts
291
Total ratings
41.8%
Success rate
15%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKTS Aktis Oncology | Initiated Coverage: Buy | $40 | $22.11 | +80.91% | 1 | Sep 9, 2026 | |
| PHVS Pharvaris | Reiterated: Buy | $50 → $75 | $35.20 | +113.07% | 12 | Sep 8, 2026 | |
| ALMS Alumis | Reiterated: Buy | $55 → $37 | $8.11 | +356.23% | 16 | Sep 2, 2026 | |
| PMVP PMV Pharmaceuticals | Reiterated: Buy | $5 | $1.51 | +231.13% | 18 | Sep 1, 2026 | |
| AAPG Ascentage Pharma Group International | Reiterated: Buy | $45 | $15.87 | +183.55% | 2 | Aug 21, 2026 | |
| MDWD MediWound | Reiterated: Buy | $32 → $30 | $13.95 | +115.05% | 6 | Aug 14, 2026 | |
| PTHS Pelthos Therapeutics | Reiterated: Buy | $66 → $64 | $23.24 | +175.39% | 9 | Aug 14, 2026 | |
| ACRV Acrivon Therapeutics | Reiterated: Buy | $8 | $2.15 | +272.09% | 2 | Aug 13, 2026 | |
| AVBP ArriVent BioPharma | Reiterated: Buy | $50 | $30.32 | +64.91% | 9 | Aug 13, 2026 | |
| CATX Perspective Therapeutics | Reiterated: Buy | $13 | $2.96 | +339.19% | 32 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $52 → $48 | $7.88 | +509.52% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $13.44 | +145.54% | 18 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $11 | $3.73 | +194.91% | 1 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $40 | $23.34 | +71.38% | 2 | Jun 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $2.38 | +950.42% | 22 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $5.72 | +74.83% | 2 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 → $40 | $11.26 | +255.24% | 9 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $7 | $4.04 | +73.27% | 4 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $86 | $32.42 | +165.27% | 7 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.23 | - | 20 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $120 | $122.06 | -1.69% | 12 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 → $16 | $4.51 | n/a | 4 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $20 | $5.82 | n/a | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.14 | n/a | 22 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.02 | n/a | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.83 | n/a | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.565 | n/a | 5 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.02 | n/a | 4 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.9277 | n/a | 4 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $3.27 | n/a | 3 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | Jul 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $0.0112 | n/a | 1 | Sep 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $47.39 | n/a | 1 | Jun 22, 2021 |
Aktis Oncology
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $22.11
Upside: +80.91%
Pharvaris
Sep 8, 2026
Reiterated: Buy
Price Target: $50 → $75
Current: $35.20
Upside: +113.07%
Alumis
Sep 2, 2026
Reiterated: Buy
Price Target: $55 → $37
Current: $8.11
Upside: +356.23%
PMV Pharmaceuticals
Sep 1, 2026
Reiterated: Buy
Price Target: $5
Current: $1.51
Upside: +231.13%
Ascentage Pharma Group International
Aug 21, 2026
Reiterated: Buy
Price Target: $45
Current: $15.87
Upside: +183.55%
MediWound
Aug 14, 2026
Reiterated: Buy
Price Target: $32 → $30
Current: $13.95
Upside: +115.05%
Pelthos Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $66 → $64
Current: $23.24
Upside: +175.39%
Acrivon Therapeutics
Aug 13, 2026
Reiterated: Buy
Price Target: $8
Current: $2.15
Upside: +272.09%
ArriVent BioPharma
Aug 13, 2026
Reiterated: Buy
Price Target: $50
Current: $30.32
Upside: +64.91%
Perspective Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $13
Current: $2.96
Upside: +339.19%
Aug 7, 2026
Reiterated: Buy
Price Target: $52 → $48
Current: $7.88
Upside: +509.52%
Aug 7, 2026
Reiterated: Buy
Price Target: $33
Current: $13.44
Upside: +145.54%
Jul 31, 2026
Initiated Coverage: Buy
Price Target: $11
Current: $3.73
Upside: +194.91%
Jun 18, 2026
Reiterated: Buy
Price Target: $40
Current: $23.34
Upside: +71.38%
May 15, 2026
Reiterated: Buy
Price Target: $25
Current: $2.38
Upside: +950.42%
May 8, 2026
Reiterated: Buy
Price Target: $10
Current: $5.72
Upside: +74.83%
May 8, 2026
Reiterated: Buy
Price Target: $41 → $40
Current: $11.26
Upside: +255.24%
May 8, 2026
Reiterated: Buy
Price Target: $6 → $7
Current: $4.04
Upside: +73.27%
Apr 20, 2026
Reiterated: Buy
Price Target: $86
Current: $32.42
Upside: +165.27%
Mar 2, 2026
Rated: Hold
Price Target: n/a
Current: $2.23
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $120
Current: $122.06
Upside: -1.69%
Aug 15, 2025
Reiterated: Buy
Price Target: $17 → $16
Current: $4.51
Upside: n/a
Aug 14, 2025
Reiterated: Buy
Price Target: $19 → $20
Current: $5.82
Upside: n/a
Aug 8, 2025
Reiterated: Hold
Price Target: n/a
Current: $1.14
Upside: n/a
Oct 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.02
Upside: n/a
Aug 14, 2024
Reiterated: Hold
Price Target: n/a
Current: $4.83
Upside: n/a
Nov 30, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.565
Upside: n/a
Nov 10, 2023
Reiterated: Hold
Price Target: n/a
Current: $1.02
Upside: n/a
Nov 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $0.9277
Upside: n/a
Apr 28, 2023
Rated: Buy
Price Target: n/a
Current: $3.27
Upside: n/a
Jul 20, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Sep 30, 2021
Reiterated: Hold
Price Target: n/a
Current: $0.0112
Upside: n/a
Jun 22, 2021
Reiterated: Buy
Price Target: $37
Current: $47.39
Upside: n/a